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Hypertrophic cardiomyopathy was first recognized from
pathologic studies in 1958 (1) and subsequently analyzed in
detail from hemodynamic (2), echocardiographic (3) and
electrophysiologic standpoints (4). It is characterized by a
hypertrophied heart with a nondilated left ventricular cham-
ber in the absence of any illness that induces an increased
myocardial mass. It is frequently associated with dynamic
left ventricular outflow obstruction, mitral regurgitation and
left ventricular diastolic dysfunction due to impaired relax-
ation processes and reduced compliance (5). It is also
associated with a relatively high prevalence of supraventric-
ular (11% to 54%) and ventricular (19% to 88%) arrhythmias
(6), a significant annual mortality rate (3% to 4%) and an
alarming incidence rate of sudden cardiac death (2% annu-
ally, accounting for over half of all cardiac deaths in this
disease) (7). Interestingly, the major risk factors for mortal-
ity in patients with hypertrophic cardiomyopathy are clini-
cally and arrhythmia related and are unrelated to hemody-
namic variables. These include younger age at diagnosis
«20 years), family history of hypertrophic cardiomyopathy
and sudden death, history of syncope, history of severe
exertional dyspnea and occurrence of complex ventricular
ectopic rhythm and nonsustained ventricular tachycardia, or
both (8).
Impact of atrial fibrillation. The occurrence of atrial
fibrillation in patients with hypertrophic cardiomyopathy has
been associated with such marked clinical and hemodynamic
deterioration (including acute pulmonary edema, angina,
syncope, hypotension and systolic embolization [5]) that it
has been assumed to engender a poor prognosis in these
patients. Sporadic reports with small numbers of cases seem
to confirm this impression (9). Indeed, this assumption has
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prompted some investigators experienced in hypertrophic
cardiomyopathy to recommend any and all therapeutic in-
terventions to suppress atrial fibrillation, including septal
myotomy or myomectomy. Unfortunately, previous reports
(9) suggest that, although conversion to sinus rhythm is
common, its maintenance, particularly in patients with an
enlarged left atrium, is unusual. Also, pathophysiologic
considerations have suggested that merely controlling the
ventricular rate of the atrial fibrillation is not sufficient to
prevent clinical deterioration and that its persistence often
leads to exertional symptoms and the development of con-
gestive heart failure (9). Thus, the occurrence of atrial
fibrillation in hypertrophic cardiomyopathy has been called
"an ominous milestone" in its clinical course (9).
Present study. In this issue of the Journal, Robinson et al.
(10) reexamine the impact of atrial fibrillation on the natural
history of hypertrophic cardiomyopathy in an important way
that changes our perspective on the influence of this arrhyth-
mia. Their study utilized a much larger patient group with a
longer duration of follow-up than previous studies and
generated a comparison of mortality statistics with a large
group of concurrent control subjects who were well matched
for mortality risk factors. The key new observations in this
study are the following: 1) the onset of atrial fibrillation in
hypertrophic cardiomyopathy is not uniformly associated
with severe clinical and hemodynamic deterioration (26% of
the study group showed no change in functional status with
the onset of atrial fibrillation); 2) failure to maintain sinus
rhythm and to restore atrial systole does not imply a wors-
ening functional status (82% of patients remaining in atrial
fibrillation returned to their baseline functional status); 3)
maintenance of sinus rhythm after pharmacologic or electri-
cal cardioversion, or both, can be achieved in a higher
percent of patients (63%) than previously thought; 4) long-
term survival in patients with hypertrophic cardiomyopathy
and atrial fibrillation is much better than previously sus-
pected and not significantly less than that in patients remain-
ing in sinus rhythm; and 5) amiodarone may have a particu-
larly beneficial effect in controlling atrial fibrillation and
reducing the associated incidence of embolic complications.
Previous studies. These findings are in distinct contrast to
those of a previous report (9) that noted much higher
mortality rates with the development of atrial fibrillation,
more frequent recurrence of the arrhythmia after initial
conversion and consistent worsening of clinical status with
its persistence. These discrepancies are due in part to the
smaller number of patients and the shorter duration of
follow-up in the previous study (9) and in part to patient
selection. The patients in the present study are more repre-
sentative of the currently recognized diversity in hemody-
namic subgroups of hypertrophic cardiomyopathy: only half
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of them had obstruction at rest (the remainder had latent or no
obstruction) and only 35% had moderate to severe mitral
regurgitation. The previous study (9) comprised patients with
obstruction at rest only and a 63% prevalence of significant
mitral regurgitation. Because obstruction at rest and mitral
regurgitation generally correlate with more extensive ventric-
ular hypertrophy (5) and because this in turn is associated
with an increased degree of diastolic dysfunction (II), pro-
gressive clinical deterioration and the occurrence of complex
ventricular arrhythmias (6), the patients in the previous study
would have a built-in higher mortality rate. Atrial fibrillation
would also be expected to develop in these patients because
of worsening diastolic dysfunction, left atrial and ventricular
dilation and the onset ofcongestive heart failure rather than as
a primary electrical phenomenon. This is supported by the
observation that the time of appearance of atrial fibrillation
after a diagnosis of hypertrophic cardiomyopathy averaged 18
years in the previous study (9) compared with only 2 years in
the present study (10). Furthermore, the development of atrial
fibrillation in such a patient group would also be expected to
have more dire hemodynamic consequences when superim-
posed on the preexisting severe diastolic dysfunction and left
ventricular outflow obstruction than in the patient group from
the present study.
Role of amiodarone in reducing mortality. An additional
explanation for the improved mortality rate observed in the
present study (10) compared with that in previous studies
may be related to newer therapies for atrial fibrillation,
particularly amiodarone. Amiodarone has recently been
shown to reduce the overall mortality rate in patients with
hypertrophic cardiomyopathy, mainly by reducing the rate of
sudden cardiac death (12). Because amiodarone was not
readily available before 1980, this difference could account for
the lower mortality rate in the present study. Furthermore,
amiodarone's documented suppression of nonsustained ven-
tricular tachycardia and associated reduction of the rate of
sudden death would be expected to have a greater impact on
mortality rates in the age group with the highest prevalence of
sudden death, that is, patients aged <20 years. It is intriguing
that the improvement in mortality rates demonstrated in the
present study is concentrated in this younger age group,
where the mortality rate for patients with atrial fibrillation (0
of 6 patients) was not statistically different from that for
patients remaining in sinus rhythm (II of 35 patients). In
contrast, in the older age group (>20 years), the mortality rate
was significantly greater in patients with atrial fibrillation (22
of 46 patients) than in those remaining in sinus rhythm (17 of
87 patients). This documented age-dependent difference in the
improvement of mortality rates for patients with hypertrophic
cardiomyopathy and atrial fibrillation compared with the rates
in patients without atrial fibrillation strongly supports a caus-
ative role for amiodarone in reducing mortality in this group of
patients. The liberal use of amiodarone, particularly in the
younger patients (perhaps related to the higher percentage of
younger compared with older patients diagnosed after 1980)
may also explain the otherwise unexpectedly low mortality
rate for the younger patients in the present study (0 of 6
patients). However, the small size of this group may have
skewed the mortality results, and further investigations will
be necessary to confirm the apparently remarkable efficacy of
amiodarone in reducing mortality.
In summary, Robinson et al. (10), by analyzing a larger
and more representative group of patients with hypertrophic
cardiomyopathy and atrial fibrillation and by following them
up by obtaining detailed clinical echocardiographic and
hemodynamic data over a long period of time, have altered
our perspective on the impact of atrial fibrillation on the
natural history of hypertrophic cardiomyopathy. They have
also suggested the possibility of a very important role for
amiodarone in the treatment of atrial fibrillation in patients
with hypertrophic cardiomyopathy.
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